The financing environment remains extremely challenging for emerging biotech R&D companies, particularly in the early-stage phase. The biotech leaders and their investors constantly try to balance the ‘Borrow-Buy-Build’ dynamic of accessing the expertise and capacity they require to move their programmes forward in the most capital efficient manner.
![]() |
Following extremely positive feedback about our last ‘Working Dinner’ held in May. It was a facilitated discussion over dinner across the room of 40-50 diners that enabled a very candid, open and insightful exchange of ideas, shared challenges, potential solutions and meaningful connections. We felt therefore, adding value beyond straight networking, we would deliver another Working Dinner to explore another key challenge – how to strategically maximising capital efficiency and value creation in a biotech by leveraging CDMOs. |
A question for each course, the evening will discuss factors and best practice in areas such as:
• Deciding what to outsource and aligning with investor expectations when pitching for investment.
• CDMO selection process: where to start, criteria to set, deal structure and making the best fit choice.
• Working with the CDMO - communication, internal vs external data sharing, IP protection and managing change.
How to attend:
Full Table: 10 spaces and profiled as a dinner sponsor - £600 + VAT
Half Table: 5 places - £300 + VAT
Single Tickets: individual tickets - £60 + VAT
One Nucleus Working Dinner – Working with CDMOs to Maximise Biotech Company Value Creation
Stow-cum-Quy
Cambridge, CB25 9AF
United Kingdom
